Last reviewed · How we verify
ETHINYL ESTRADIOL AND LEVOGESTREL
This combination oral contraceptive prevents pregnancy by suppressing ovulation through hormonal inhibition of the hypothalamic-pituitary-ovarian axis.
This combination oral contraceptive prevents pregnancy by suppressing ovulation through hormonal inhibition of the hypothalamic-pituitary-ovarian axis. Used for Contraception / prevention of pregnancy.
At a glance
| Generic name | ETHINYL ESTRADIOL AND LEVOGESTREL |
|---|---|
| Sponsor | FHI 360 |
| Drug class | Combined oral contraceptive |
| Target | Estrogen receptor and progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Reproductive Health |
| Phase | FDA-approved |
Mechanism of action
Ethinyl estradiol (a synthetic estrogen) and levonorgestrel (a synthetic progestin) work synergistically to inhibit the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), preventing ovulation. The progestin component also thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.
Approved indications
- Contraception / prevention of pregnancy
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ETHINYL ESTRADIOL AND LEVOGESTREL CI brief — competitive landscape report
- ETHINYL ESTRADIOL AND LEVOGESTREL updates RSS · CI watch RSS
- FHI 360 portfolio CI